Table 5. Cost (CHF) per patient and cost-effectiveness results in genotype 1.
| Indication | Parameter | Intervention | Comparator | Δ | Comparator | Δ | Comparator | Δ | Comparator | Δ |
|---|---|---|---|---|---|---|---|---|---|---|
| GT1 TN IE | SOF+PaR 12 wks | PaR 48 wks | PbR 48 wks | TEL+PaR 48 wks | BOC+PbR 48 wks | |||||
| Drug costs | 62,862 | 20,454 | 42,408 | 20,875 | 41,987 | 49,333 | 13,529 | 45,135 | 17,727 | |
| AE costs | 15 | 2,064 | -2,049 | 2,064 | -2,049 | 3,086 | -3,071 | 56 | -41 | |
| Monitoring costs | 3,279 | 4,650 | -1,371 | 4,650 | -1,371 | 4,115 | -836 | 4,404 | -1,125 | |
| Total treatment costs | 66,156 | 27,168 | 38,988 | 27,589 | 38,567 | 56,534 | 9,622 | 49,595 | 16,561 | |
| Health state costs | 8,646 | 24,403 | -15,757 | 24,398 | -15,752 | 13,986 | -5,340 | 16,897 | -8,251 | |
| Total cost per patient | 74,802 | 51,571 | 23,231 | 51,987 | 22,815 | 70,520 | 4,282 | 66,492 | 8,310 | |
| QALYs per patient* | 13.3 | 12.1 | 1.2 | 12.1 | 1.2 | 12.9 | 0.4 | 12.7 | 0.6 | |
| GT1 TN II | SOF+RBV 24 wks | NT | Δ | |||||||
| Drug costs | 120,184 | 0 | 120,184 | |||||||
| AE costs | 40 | 0 | 40 | |||||||
| Monitoring costs | 3,502 | 1,472 | 2,030 | |||||||
| Total treatment costs | 123,726 | 1,472 | 122,254 | |||||||
| Health state costs | 19,070 | 35,964 | -16,894 | |||||||
| Total cost per patient | 142,796 | 37,436 | 105,360 | |||||||
| QALYs per patient* | 12.6 | 11.4 | 1.2 |
AE, adverse event; BOC, boceprevir; GT, genotype; IE, interferon eligible; II, interferon ineligible; NT, no treatment; PaR, pegylated interferon alpha+ribavirin; PbR, pegylated interferon beta+ribavirin; QALY, quality-adjusted life year; RBV, ribavirin; SOF, sofosbuvir; TEL, telaprevir; TN, treatment-naïve
* values are rounded to one decimal place